Leukemia - Table of Contents alert Volume 28 Issue 1

If you are unable to see the message below, click here to view.

Advertisement BD FACSCanto™ has 10-color capability.  Reliable performance, accuracy, and ease of use make the latest BD FACSCanto System a perfect 10 for today's busy clinical labs. Learn how you can achieve dependable outcomes while speeding workflow and reducing training requirements with clinical multi-color flow cytometry systems from BD Biosciences.  bdbiosciences.com/go/canto TABLE OF CONTENTS Volume 28, Issue 1 (January 2014) In this issue Spotlight Review Reviews Concise Review Original Articles Letters to the Editor Also new AOP Sign up for e-alerts Recommend to your library Web feed Follow on Twitter Subscribe Advertisement NATURE REVIEWS CANCER & NATURE REVIEWS CLINICAL ONCOLOGY 2014 CALENDAR Download the calendar for FREE As well as plundering the Nature Reviews Cancer image bank for more clinically oriented figures for our 2014 calendar, we have chosen six images and figures from our sister journal, Nature Reviews Clinical Oncology. Our calendar is freely available thanks to support from  OriGene  Spotlight Review Top SPOTLIGHT ON EPIGENETICS IN HEMATOLOGIC MALIGNANCIES Origins of aberrant DNA methylation in acute myeloid leukemia T Schoofs, W E Berdel and C Müller-Tidow Leukemia 2014 28: 1-14; advance online publication, August 20, 2013; 10.1038/leu.2013.242 Abstract | Full Text Reviews Top Multifaceted roles of GSK-3 and Wnt/β-catenin in hematopoiesis and leukemogenesis: opportunities for therapeutic intervention OPEN J A McCubrey, L S Steelman, F E Bertrand, N M Davis, S L Abrams, G Montalto, A B D'Assoro, M Libra, F Nicoletti, R Maestro, J Basecke, L Cocco, M Cervello and A M Martelli Leukemia 2014 28: 15-33; advance online publication, June 19, 2013; 10.1038/leu.2013.184 Abstract | Full Text Clonal evolution in hematological malignancies and therapeutic implications D A Landau, S L Carter, G Getz and C J Wu Leukemia 2014 28: 34-43; advance online publication, August 27, 2013; 10.1038/leu.2013.248 Abstract | Full Text Concise Review Top EZH2 in normal and malignant hematopoiesis K Lund, P D Adams and M Copland Leukemia 2014 28: 44-49; advance online publication, October 7, 2013; 10.1038/leu.2013.288 Abstract | Full Text Original Articles Top ACUTE LEUKEMIAS Integration of cytogenetic and molecular alterations in risk stratification of 318 patients with de novo non-M3 acute myeloid leukemia H-A Hou, C-C Lin, W-C Chou, C-Y Liu, C-Y Chen, J-L Tang, Y-J Lai, M-H Tseng, C-F Huang, Y-C Chiang, F-Y Lee, Y-Y Kuo, M-C Lee, M-C Liu, C-W Liu, L-I Lin, M Yao, S-Y Huang, B-S Ko, S-C Hsu, S-J Wu, W Tsay, Y-C Chen and H-F Tien Leukemia 2014 28: 50-58; advance online publication, August 9, 2013; 10.1038/leu.2013.236 Abstract | Full Text Costimulation improves the killing capability of T cells redirected to tumor cells expressing low levels of CD33: description of a novel modular targeting system C Arndt, A Feldmann, M von Bonin, M Cartellieri, E-M Ewen, S Koristka, I Michalk, S Stamova, N Berndt, A Gocht, M Bornhäuser, G Ehninger, M Schmitz and M Bachmann Leukemia 2014 28: 59-69; advance online publication, August 20, 2013; 10.1038/leu.2013.243 Abstract | Full Text An intragenic ERG deletion is a marker of an oncogenic subtype of B-cell precursor acute lymphoblastic leukemia with a favorable outcome despite frequent IKZF1 deletions E Clappier, M-F Auclerc, J Rapion, M Bakkus, A Caye, A Khemiri, C Giroux, L Hernandez, E Kabongo, S Savola, T Leblanc, K Yakouben, G Plat, V Costa, A Ferster, S Girard, O Fenneteau, J-M Cayuela, F Sigaux, N Dastugue, S Suciu, Y Benoit, Y Bertrand, J Soulier and H Cavé Leukemia 2014 28: 70-77; advance online publication, September 25, 2013; 10.1038/leu.2013.277 Abstract | Full Text MYELODYSPLASIAS Impact of molecular mutations on treatment response to DNMT inhibitors in myelodysplasia and related neoplasms F Traina, V Visconte, P Elson, A Tabarroki, A M Jankowska, E Hasrouni, Y Sugimoto, H Szpurka, H Makishima, C L O'Keefe, M A Sekeres, A S Advani, M Kalaycio, E A Copelan, Y Saunthararajah, S T Olalla Saad, J P Maciejewski and R V Tiu Leukemia 2014 28: 78-87; advance online publication, September 18, 2013; 10.1038/leu.2013.269 Abstract | Full Text CHRONIC MYELOPROLIFERATIVE NEOPLASIAS BET protein inhibition shows efficacy against JAK2V617F-driven neoplasms B S Wyspiańska, A J Bannister, I Barbieri, J Nangalia, A Godfrey, F J Calero-Nieto, S Robson, I Rioja, J Li, M Wiese, E Cannizzaro, M A Dawson, B Huntly, R K Prinjha, A R Green, B Gottgens and T Kouzarides Leukemia 2014 28: 88-97; advance online publication, August 9, 2013; 10.1038/leu.2013.234 Abstract | Full Text CHRONIC LYMPHOCYTIC LEUKEMIA Defective DROSHA processing contributes to downregulation of MiR-15/-16 in chronic lymphocytic leukemia D Allegra, V Bilan, A Garding, H Döhner, S Stilgenbauer, F Kuchenbauer and D Mertens Leukemia 2014 28: 98-107; advance online publication, August 26, 2013; 10.1038/leu.2013.246 Abstract | Full Text SF3B1 mutations correlated to cytogenetics and mutations in NOTCH1, FBXW7, MYD88, XPO1 and TP53 in 1160 untreated CLL patients S Jeromin, S Weissmann, C Haferlach, F Dicker, K Bayer, V Grossmann, T Alpermann, A Roller, A Kohlmann, T Haferlach, W Kern and S Schnittger Leukemia 2014 28: 108-117; advance online publication, September 12, 2013; 10.1038/leu.2013.263 Abstract | Full Text Loss of p53 and altered miR15-a/16-1→MCL-1 pathway in CLL: insights from TCL1-Tg:p53−/− mouse model and primary human leukemia cells J Liu, G Chen, L Feng, W Zhang, H Pelicano, F Wang, M A Ogasawara, W Lu, H M Amin, C M Croce, M J Keating and P Huang Leukemia 2014 28: 118-128; advance online publication, April 23, 2013; 10.1038/leu.2013.125 Abstract | Full Text CYTOGENETICS AND MOLECULAR GENETICS Monitoring of residual disease by next-generation deep-sequencing of RUNX1 mutations can identify acute myeloid leukemia patients with resistant disease A Kohlmann, N Nadarajah, T Alpermann, V Grossmann, S Schindela, F Dicker, A Roller, W Kern, C Haferlach, S Schnittger and T Haferlach Leukemia 2014 28: 129-137; advance online publication, August 20, 2013; 10.1038/leu.2013.239 Abstract | Full Text TRANSCRIPTIONAL CONTROL AND SIGNAL TRANSDUCTION Regulation of MEIS1 by distal enhancer elements in acute leukemia Q-f Wang, Y-j Li, J-f Dong, B Li, J J Kaberlein, L Zhang, F E Arimura, R T Luo, J Ni, F He, J Wu, R Mattison, J Zhou, C-z Wang, S Prabhakar, M A Nobrega and M J Thirman Leukemia 2014 28: 138-146; advance online publication, September 11, 2013; 10.1038/leu.2013.260 Abstract | Full Text LYMPHOMA Epigenetic mechanisms of protein tyrosine phosphatase 6 suppression in diffuse large B-cell lymphoma: implications for epigenetic therapy T E Witzig, G Hu, S M Offer, L E Wellik, J J Han, M J Stenson, A Dogan, R B Diasio and M Gupta Leukemia 2014 28: 147-154; advance online publication, August 27, 2013; 10.1038/leu.2013.251 Abstract | Full Text MYELOMA CRM1 inhibition induces tumor cell cytotoxicity and impairs osteoclastogenesis in multiple myeloma: molecular mechanisms and therapeutic implications Y-T Tai, Y Landesman, C Acharya, Y Calle, M Y Zhong, M Cea, D Tannenbaum, A Cagnetta, M Reagan, A A Munshi, W Senapedis, J-R Saint-Martin, T Kashyap, S Shacham, M Kauffman, Y Gu, L Wu, I Ghobrial, F Zhan, A L Kung, S A Schey, P Richardson, N C Munshi and K C Anderson Leukemia 2014 28: 155-165; advance online publication, April 16, 2013; 10.1038/leu.2013.115 Abstract | Full Text Multiparameter flow cytometry for the identification of the Waldenström’s clone in IgM-MGUS and Waldenström’s Macroglobulinemia: new criteria for differential diagnosis and risk stratification B Paiva, M C Montes, R García-Sanz, E M Ocio, J Alonso, N de las Heras, F Escalante, R Cuello, A G de Coca, J Galende, J Hernández, M Sierra, A Martin, E Pardal, A Bárez, J Alonso, L Suarez, T J González-López, J J Perez, A Orfao, M-B Vidríales and J F San Miguel Leukemia 2014 28: 166-173; advance online publication, April 22, 2013; 10.1038/leu.2013.124 Abstract | Full Text Prognostic significance of whole-body MRI in patients with monoclonal gammopathy of undetermined significance J Hillengass, M-A Weber, K Kilk, K Listl, B Wagner-Gund, M Hillengass, T Hielscher, A Farid, K Neben, S Delorme, O Landgren and H Goldschmidt Leukemia 2014 28: 174-178; advance online publication, August 20, 2013; 10.1038/leu.2013.244 Abstract | Full Text Letters to the Editor Top Activity of the clinical-stage CK2-specific inhibitor CX-4945 against chronic lymphocytic leukemia L R Martins, P Lúcio, A Melão, I Antunes, B A Cardoso, R Stansfield, M T S Bertilaccio, P Ghia, D Drygin, M G Silva and J T Barata Leukemia 2014 28: 179-182; advance online publication, August 8, 2013; 10.1038/leu.2013.232 Full Text ERG deletion is associated with CD2 and attenuates the negative impact of IKZF1 deletion in childhood acute lymphoblastic leukemia M Zaliova, O Zimmermannova, P Dörge, C Eckert, A Möricke, M Zimmermann, J Stuchly, A Teigler-Schlegel, B Meissner, R Koehler, C R Bartram, L Karawajew, P Rhein, J Zuna, M Schrappe, G Cario and M Stanulla Leukemia 2014 28: 182-185; advance online publication, September 27, 2013; 10.1038/leu.2013.282 Full Text Application of the International Prognostic Scoring System-Revised in therapy-related myelodysplastic syndromes and oligoblastic acute myeloid leukemia C Y Ok, R P Hasserjian, P S Fox, F Stingo, Z Zuo, K H Young, K Patel, L J Medeiros, G Garcia-Manero and S A Wang Leukemia 2014 28: 185-189; advance online publication, June 21, 2013; 10.1038/leu.2013.191 Full Text The clinical relevance of minor paroxysmal nocturnal hemoglobinuria clones in refractory cytopenia of childhood: a prospective study by EWOG-MDS A M Aalbers, V H J van der Velden, A Yoshimi, A Fischer, P Noellke, C M Zwaan, I Baumann, H B Beverloo, M Dworzak, H Hasle, F Locatelli, B De Moerloose, G Göhring, M Schmugge, J Stary, M Zecca, A W Langerak, J J M van Dongen, R Pieters, C M Niemeyer and M M van den Heuvel-Eibrink Leukemia 2014 28: 189-192; advance online publication, June 28, 2013; 10.1038/leu.2013.195 Full Text Efficient generation of human natural killer cell lines by viral transformation B Vogel, K Tennert, F Full and A Ensser Leukemia 2014 28: 192-195; advance online publication, June 21, 2013; 10.1038/leu.2013.188 Full Text Detecting dic(9;20)(p13.2;p11.2)-positive B-cell precursor acute lymphoblastic leukemia in a clinical setting using fluorescence in situ hybridization V Zachariadis, J Schoumans, I Öfverholm, G Barbany, E Halvardsson, E Forestier, B Johansson, M Nordenskjöld and A Nordgren Leukemia 2014 28: 196-198; advance online publication, June 21, 2013; 10.1038/leu.2013.189 Full Text Point mutation E1099K in MMSET/NSD2 enhances its methyltranferase activity and leads to altered global chromatin methylation in lymphoid malignancies J A Oyer, X Huang, Y Zheng, J Shim, T Ezponda, Z Carpenter, M Allegretta, C I Okot-Kotber, J P Patel, A Melnick, R L Levine, A Ferrando, A D MacKerell, Jr, N L Kelleher, J D Licht and R Popovic Leukemia 2014 28: 198-201; advance online publication, July 4, 2013; 10.1038/leu.2013.204 Full Text Understanding the mutational evolution of clonal cytopenias and oligoblastic myelogenous leukemia (‘myelodysplasia’) M A Lichtman Leukemia 2014 28: 202; advance online publication, July 11, 2013; 10.1038/leu.2013.209 Full Text mTOR kinase inhibitor sensitizes T-cell lymphoblastic leukemia for chemotherapy-induced DNA damage via suppressing FANCD2 expression F Guo, J Li, S Zhang, W Du, S Amarachintha, J Sipple, J Phelan, H L Grimes, Y Zheng and Q Pang Leukemia 2014 28: 203-206; advance online publication, July 15, 2013; 10.1038/leu.2013.215 Full Text Dasatinib promotes the potential of proliferation and antitumor responses of human γδT cells in a long-term induction ex vivo environment K-n Wu, Y-j Wang, Y He, Y-x Hu, H-r Fu, L-x Sheng, B-s Wang, S Fu and H Huang Leukemia 2014 28: 206-210; advance online publication, July 22, 2013; 10.1038/leu.2013.221 Full Text The Bcl-2 specific BH3 mimetic ABT-199: a promising targeted therapy for t(11;14) multiple myeloma OPEN C Touzeau, C Dousset, S Le Gouill, D Sampath, J D Leverson, A J Souers, S Maïga, M C Béné, P Moreau, C Pellat-Deceunynck and M Amiot Leukemia 2014 28: 210-212; advance online publication, July 17, 2013; 10.1038/leu.2013.216 Full Text PAX5 overexpression is not enough to reestablish the mature B-cell phenotype in classical Hodgkin lymphoma L Dimitrova, V Seitz, J Hecht, D Lenze, P Hansen, M Szczepanowski, L Ma, E Oker, A Sommerfeld, F Jundt, W Klapper and M Hummel Leukemia 2014 28: 213-216; advance online publication, July 11, 2013; 10.1038/leu.2013.211 Full Text VPREB1 deletions occur independent of lambda light chain rearrangement in childhood acute lymphoblastic leukemia D S Mangum, J Downie, C C Mason, M S Jahromi, D Joshi, V Rodic, M Müschen, N Meeker, N Trede, J K Frazer, Y Zhou, C Cheng, S Jeha, C-H Pui, C L Willman, R C Harvey, S P Hunger, J J Yang, P Barnette, C G Mullighan, R R Miles and J D Schiffman Leukemia 2014 28: 216-220; advance online publication, July 24, 2013; 10.1038/leu.2013.223 Full Text Bilateral corneal infections associated with topical steroid therapy prophylaxis for cytarabine arabinoside-induced keratoconjunctivitis C Samarawickrama, A S Ioannidis, A W Wechsler and S L Watson Leukemia 2014 28: 220-222; advance online publication, August 13, 2013; 10.1038/leu.2013.237 Full Text Lenalidomide and low-dose dexamethasone for newly diagnosed primary plasma cell leukemia P Musto, V Simeon, M C Martorelli, M T Petrucci, N Cascavilla, F Di Raimondo, T Caravita, F Morabito, M Offidani, A Olivieri, G Benevolo, R Mina, R Guariglia, G D'Arena, G Mansueto, N Filardi, F Nobile, A Levi, A Falcone, M Cavalli, G Pietrantuono, O Villani, S Bringhen, P Omedè, R Lerose, L Agnelli, K Todoerti, A Neri, M Boccadoro and A Palumbo Leukemia 2014 28: 222-225; advance online publication, August 20, 2013; 10.1038/leu.2013.241 Full Text Reactivation of hepatitis B virus infection following ruxolitinib treatment in a patient with myelofibrosis G Caocci, F Murgia, L Podda, A Solinas, S Atzeni and G La Nasa Leukemia 2014 28: 225-227; advance online publication, August 9, 2013; 10.1038/leu.2013.235 Full Text Expression of the lymphoid enhancer factor 1 is required for normal hematopoietic stem and progenitor cell function K E Edmaier, K Stahnke, N Vegi, M Mulaw, S Ihme, A Scheffold, K L Rudolph and C Buske Leukemia 2014 28: 227-230; advance online publication, August 14, 2013; 10.1038/leu.2013.238 Full Text Antibody-dependent cellular cytotoxicity of the optimized anti-CD20 monoclonal antibody ublituximab on chronic lymphocytic leukemia cells with the 17p deletion M Le Garff-Tavernier, L Herbi, C de Romeuf, F Nguyen-Khac, F Davi, A Grelier, M Boudjoghra, K Maloum, S Choquet, R Urbain, V Vieillard and H Merle-Béral Leukemia 2014 28: 230-233; advance online publication, August 20, 2013; 10.1038/leu.2013.240 Full Text Overexpression of SNORD114-3 marks acute promyelocytic leukemia T Liuksiala, K J Teittinen, K Granberg, M Heinäniemi, M Annala, M Mäki, M Nykter and O Lohi Leukemia 2014 28: 233-236; advance online publication, August 27, 2013; 10.1038/leu.2013.250 Full Text Harnessing PD-L1-specific cytotoxic T cells for anti-leukemia immunotherapy to defeat mechanisms of immune escape mediated by the PD-1 pathway S M Ahmad, S K Larsen, I M Svane and M H Andersen Leukemia 2014 28: 236-238; advance online publication, September 12, 2013; 10.1038/leu.2013.261 Full Text Advertisement The new Cancer Gene Therapy CGT has a new editor in chief with a new vision for the journal: Steven K. Libutti, M.D. - Director of Montefiore-Einstein Center for Cancer Care - Associate Director for Clinical Services, Albert Einstein Cancer Center.  Submit your research and be a part of the new Cancer Gene Therapy. You can follow CGT on Twitter @cgtnature Natureevents is a fully searchable, multi-disciplinary database designed to maximise exposure for events organisers. The contents of the Natureevents Directory are now live. The digital version is available here. Find the latest scientific conferences, courses, meetings and symposia on natureevents.com. For event advertising opportunities across the Nature Publishing Group portfolio please contact natureevents@nature.com More Nature Events Please note that you need to be a subscriber or site-licence holder to enjoy full-text access to Leukemia. In order to do so, please purchase a subscription. You have been sent this Table of Contents Alert because you have opted in to receive it. You can change or discontinue your e-mail alerts at any time, by modifying your preferences on your nature.com account at: www.nature.com/nams/svc/myaccount (You will need to log in to be recognised as a nature.com registrant). For further technical assistance, please contact our registration department. For print subscription enquiries, please contact our subscription department. For other enquiries, please contact our customer feedback department. Nature Publishing Group | 75 Varick Street, 9th Floor | New York | NY 10013-1917 | USA Nature Publishing Group's worldwide offices: London - Paris - Munich - New Delhi - Tokyo - Melbourne San Diego - San Francisco - Washington - New York - Boston Macmillan Publishers Limited is a company incorporated in England and Wales under company number 785998 and whose registered office is located at Brunel Road, Houndmills, Basingstoke, Hampshire RG21 6XS. © 2014 Nature Publishing Group, a division of Macmillan Publishers Limited. All Rights Reserved.